Cargando…
Loading, please waitCargando…
Loading, please waitCondition Guide
A clear, physician-led overview of how mesenchymal stem cell (MSC) therapy is being studied as an investigational, minimally invasive option for chronic low back pain caused by degenerative disc disease (DDD). What the current randomized evidence really shows, when intradiscal MSC therapy may be considered alongside conservative spine care, who is and isn't a candidate — and how our team at Regeneris Therapy in Cancún, México evaluates each case under COFEPRIS oversight.
Degenerative disc disease (DDD) is a structural and biological condition of the intervertebral disc that can cause chronic low back pain. At Regeneris Therapy in Cancún, México, mesenchymal stem cell (MSC) therapy for DDD is offered only as a physician-supervised investigational option for selected patients who have not responded adequately to a structured course of conservative spine care. Among regenerative indications, DDD has one of the more developed randomized human datasets — Phase I/II trials and a 2021 meta-analysis report meaningful reductions in pain (VAS) and disability (ODI) versus controls, with a generally favorable short-to-mid-term safety profile — but the field still classifies intradiscal MSC therapy as promising rather than established. Every plan begins with a free medical evaluation, after which patients receive a personalized written quote — Regeneris does not publish prices.
Clinical overview
Degenerative disc disease (DDD) is not really a single "disease" — it is the gradual, age-related and biomechanical degeneration of the intervertebral discs, the soft cushions between the vertebrae of the spine. With time the inner nucleus pulposus loses water and matrix proteoglycans, disc height decreases, the outer annulus fibrosus can fissure, and the local environment becomes pro-inflammatory. In some people this remains painless; in others it produces chronic mechanical low back pain (or neck pain in the cervical spine), referred pain, stiffness, and reduced function. Diagnosis is clinical and supported by MRI (most commonly using the Pfirrmann grading system) and is made by a spine specialist — never by a regenerative protocol alone. Standard, evidence-based care in Cancún, México and worldwide starts with conservative treatment; intradiscal MSC therapy is considered, when it is considered at all, only as an investigational, minimally invasive option after that pathway.
What the research shows
The honest summary is: among regenerative indications, intradiscal MSC therapy has one of the more developed randomized human datasets — but the field still classifies it as promising rather than established. Multiple Phase I/II trials, a randomized controlled trial of allogeneic bone marrow MSCs, long-term follow-up data, and a 2021 systematic review with meta-analysis of randomized trials all point in the same direction: meaningful reductions in pain (VAS) and disability (ODI) versus controls in selected patients, with a generally favorable short-to-mid-term safety profile. The literature does not yet support claims of "disc regeneration" or guaranteed avoidance of surgery. The notes below summarize four representative peer-reviewed sources we discuss with patients during evaluation in Cancún, México.
The field's own founder reframed these cells as "medicinal signaling cells," arguing that their benefit comes chiefly from secreted, paracrine factors rather than from engraftment and tissue replacement. This mechanistic framing is the basis of any rational use in a degenerated disc — modulating the pro-inflammatory environment and supporting matrix homeostasis, not regrowing the disc.
Patient selection
Candidate selection is a medical decision and depends on imaging, prior treatments, comorbidities, and goals. The lists below are a general orientation, not a self-screening tool. They reflect how our physicians in Cancún, México think about intradiscal MSC therapy in chronic discogenic low back pain.
Regulatory framework
Regeneris Therapy is a COFEPRIS-regulated regenerative medicine clinic in Cancún, Quintana Roo, México. COFEPRIS — Comisión Federal para la Protección contra Riesgos Sanitarios — is Mexico's federal health authority (equivalent in role to the U.S. FDA). Our operating authorizations and supervised physician model are the foundation of every protocol we offer, including any intradiscal MSC therapy considered as part of a chronic low back pain plan.
Regeneris Therapy operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 in Cancún, México. Our cell-source chain (Wharton's-jelly umbilical-cord MSCs, bone marrow, or adipose, depending on the protocol) is expanded in sterile, certified laboratory conditions before clinical use.
The Regeneris approach
Our pathway for any DDD inquiry in Cancún, México is the same: a free, physician-led medical evaluation comes first, then — if and only if a Regeneris physician determines intradiscal MSC therapy is an appropriate investigational option for your case — a personalized written quote is issued for your records. Regeneris does not publish prices online for any regenerative protocol.
Send us your recent imaging (lumbar or cervical MRI, ideally with Pfirrmann grading), your spine specialist's notes, a record of prior treatments, and your goals. One of our physicians reviews everything personally — never a chatbot, never a sales team.
We tell you whether intradiscal MSC therapy is a reasonable consideration in your specific case — and we tell you when it is not. If the answer is "more structured conservative care first," or "this is a surgical problem," we say so.
When MSC therapy is appropriate, we coordinate with your spine specialist whenever possible. The procedure is performed under image guidance and sterile conditions in our Cancún, México clinic, and structured follow-up is built into the plan.
Honest expectations
Setting expectations is part of the medicine. Below is what the current evidence does and does not support for intradiscal MSC therapy in degenerative disc disease. Anyone — clinic or website — promising you guaranteed disc regeneration, restored disc height, or a permanent end to all back pain in a single visit is overstating the evidence.
FAQ
The questions patients ask most about intradiscal MSC therapy for chronic low back pain from degenerative disc disease in Cancún, México.
No — and any clinic promising that is overstating the evidence. Published randomized trials and a 2021 meta-analysis show that intradiscal mesenchymal stem cell (MSC) therapy can reduce pain (VAS) and disability (ODI), and a small RCT reported MRI-quality improvements (Pfirrmann grading), but the literature does not show regrowth of disc anatomy or restoration of disc height in humans. At Regeneris Therapy in Cancún, México, MSC therapy is framed honestly: a minimally invasive, investigational option that may help selected patients — never disc regeneration.
This page is informational and does not constitute medical advice. Degenerative disc disease (DDD) is a spine condition that should be evaluated by a licensed spine specialist; standard care typically involves structured physical therapy, conservative measures, image-guided interventions, and, in selected patients, surgery. Intradiscal mesenchymal stem cell (MSC) therapy described on this page is investigational for DDD and is offered only as an option after a physician evaluation. Outcomes vary by patient, imaging, prior treatments, and protocol, and no individual outcome is guaranteed. Regeneris Therapy operates under COFEPRIS Aviso Sanitario 2323025036X00098 and Aviso de Publicidad 2323022002A00053 in Cancún, México.
Book a free 15-min call with our team.
Send your recent imaging, your specialist's notes, and a record of prior treatments. One of our physicians in Cancún, México will review your case and tell you honestly whether MSC therapy could play a role — with a personalized written quote only after a free medical evaluation.
Put plainly: DDD is a biological and structural condition of the disc; spine specialists treat it first with conservative care, image-guided interventions, and — when indicated — surgery. MSC therapy in Cancún, México is offered only as an investigational, minimally invasive option, and only when a Regeneris physician agrees it is appropriate after reviewing your imaging, prior treatments, and goals.
A pilot study by Orozco and colleagues treated ten patients with chronic low back pain due to lumbar disc degeneration with intradiscal injection of expanded autologous bone marrow MSCs. Patients exhibited rapid improvement of pain and disability (reaching ~85% of maximum response by three months), and disc water content increased significantly at twelve months on MRI, although disc height was not restored. The authors framed the approach as a feasible, less invasive alternative worth further investigation — not as an established treatment.
Noriega and colleagues randomized 24 patients with chronic back pain and lumbar disc degeneration to an intradiscal injection of allogeneic bone marrow mesenchymal stromal cells versus a sham comparator. At one-year follow-up, MSC-treated patients showed a quick and significant improvement in algofunctional indices versus controls, and disc quality on MRI (Pfirrmann grading) improved in the MSC arm while worsening in controls. The trial is small but it is one of the first controlled randomized signals for intradiscal MSC therapy in DDD.
A long-term follow-up of the same allogeneic MSC randomized trial in degenerative disc disease reported that the clinical improvements observed at one year were largely maintained over extended follow-up, supporting the durability signal of the therapy in selected patients. The authors continue to frame the approach as a logistically convenient, minimally invasive option that warrants larger confirmatory trials rather than a finished therapy.
A 2021 systematic review and meta-analysis of randomized controlled trials of human MSC therapy for degenerative disc disease pooled the available evidence and found that MSC therapy significantly decreased pain (VAS) at 3, 6, 12, and ≥24 months, and reduced disability (ODI) versus controls. Adverse events related to the procedure were uncommon and the overall safety signal was favorable, though authors emphasize the small number and modest size of trials. The meta-analytic conclusion — "therapeutic promise" — is the right altitude for honest patient conversations.
Reading the evidence together: intradiscal MSC therapy for DDD shows one of the more consistent randomized signals in the regenerative medicine literature — durable pain and disability improvement in selected patients with a generally favorable safety profile — while the field correctly classifies it as promising rather than established. That is exactly what we tell patients in Cancún, México before they decide.
There is no "yes for everyone" answer. The point of the free medical evaluation in Cancún, México is to honestly tell you whether intradiscal MSC therapy is worth considering in your specific case — and to say no when it is not.
Every evaluation, intradiscal procedure, and follow-up in Cancún, México is supervised by a licensed Mexican physician — including coordination with your treating spine specialist when appropriate. MSC therapy is never sold as an off-the-shelf product.
Our clinic is located at Av. Tulúm SM 11 MZ 1 Lote 1 Local 207, San Francisco, 77504 Cancún, Quintana Roo, México. International patients regularly fly into Cancún International Airport (CUN), and we coordinate scheduling around recovery timelines and travel logistics for a spine-care visit.
After the evaluation, you receive a written quote that reflects your individualized plan: which cell source, how many discs, follow-up cadence, and travel logistics for Cancún, México. Regeneris does not publish or quote standardized prices online.
This is deliberately a slower path than a typical retail medical website. Chronic low back pain is a complex condition; honest patient selection and honest expectations protect outcomes more than any single injection ever could.
If a clinic tells you something stronger than this, ask to see the specific peer-reviewed source — and ask whether it is in patients like you. That is exactly the conversation we expect to have with you in Cancún, México.
Generally, an adult with specialist-confirmed chronic discogenic low back pain from degenerative disc disease (typically Pfirrmann grade III–IV on MRI), with imaging concordant with symptoms, who has completed an adequate structured course of conservative spine care (physical therapy, activity and ergonomic optimization, image-guided interventions when appropriate) and remains functionally limited. Candidacy is decided in a free medical evaluation in Cancún, México — we say yes when the evidence supports it, and no when it does not.
There is no responsible way to promise that. Some randomized trials report meaningful symptomatic improvement after intradiscal MSC therapy, which may delay or avoid surgery for selected patients — but that is a possibility, not a guarantee. Surgical decisions belong with your spine specialist and are based on imaging, neurologic status, instability, and response to conservative care. Our role in Cancún, México is to give you an honest read on whether MSC therapy is worth trying first or alongside — and to say so when surgery is clearly the right call.
The procedure is a minimally invasive intradiscal injection of expanded mesenchymal stem cells, performed under image guidance and sterile conditions in our Cancún, México clinic — typically as an outpatient visit. Most patients experience some transient discomfort at the injection site for a few days; most return to light daily activity quickly, with a graded return to physical therapy and stronger activity guided by your physician. Studies report onset of pain and disability improvement that is gradual over the first weeks to months, consistent with the paracrine, anti-inflammatory mechanism of MSCs.
In published Phase I/II trials, a randomized controlled trial, and the 2021 meta-analysis, intradiscal MSC therapy for DDD has generally been reported as safe and well tolerated under qualified supervision, with procedure-related adverse events uncommon. As a general rule, elective intradiscal MSC therapy is deferred in active or recently treated malignancy, uncontrolled immunosuppression, active uncontrolled infection (especially of the disc or spine), severe end-plate compromise, and pregnancy or breastfeeding. Disclose every medication, supplement, and diagnosis at evaluation so our physicians in Cancún, México can screen you correctly and coordinate with your treating specialist when relevant.
Because Regeneris Therapy operates as a COFEPRIS-regulated regenerative medicine clinic in Cancún, México — federally authorized, physician-led, and using cells expanded in certified laboratory conditions — under a regulatory framework that allows transparent access to MSC-based protocols that remain investigational in many jurisdictions. Cancún is internationally accessible via Cancún International Airport (CUN), and many of our patients combine evaluation, the supervised intradiscal procedure, and structured follow-up around a defined visit. Our role for DDD patients is to coordinate carefully with their spine specialist at home — never to compete with that care.
Plain-text question-and-answer pairs in semantic HTML — designed to be easily extracted by AI assistants, search engines, and accessibility tools.
How regenerative medicine is regulated and supervised in México, and what to ask any clinic before you commit.